Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000526

Drug Information
NameEthosuximide
SynonymsPiknolepsin; Parke Davis Brand of Ethosuximide; Pemal; Emeside; 3-Ethyl-3-methyl-2,5-pyrrolidinedione; NSC 64013; Ethosuximidum [INN-Latin]; gamma-Methyl-gamma-ethyl-succinimide; Spectrum3_000944; CI-366; Faes Brand of Ethosuximide; E7138_SIGMA; KBio3_002008; NCGC00093923-04; 2,5-Pyrrolidinedione, 3-ethyl-3-methyl-, (+-)-; Ethosuxide; CN-10,395; HSDB 1119; Faes, Etosuximida; EU-0100532; KBio2_004433; E 7138; Zarondan-Saft; Ethosuccimid; Pyknole.psi.num; D00539; SPBio_001465; Zarontin; Zarondan; Ronton; Ethosuximide [USAN:INN:BAN:JAN]; 2,5-Pyrrolidinedione, 3-ethyl-3-methyl-; CID3291; EINECS 201-048-7; Ethosuccimide; Thilopemal; Etosuccimide; NCGC00015418-02; Simatin; Wernigerode Brand of Ethosuximide; alpha-Methyl-alpha-ethylsuccinimide; MolPort-003-666-417; Suxilep; IDI1_000218; 2-Methyl-2-ethylsuccinimide; E0746; Ethosuximide (JP15/USP/INN); Suxin; KBio2_007001; Thetamid; Petinimid; AC1L1FLN; KBioGR_001342; BPBio1_000033; Aethosuximide; Zarontin (TN); CHEBI:4887; Suximal; Spectrum_001385; KBioSS_001865; Pfizer Brand of Ethosuximide; Aethosuccimidum; Desitin Brand of Ethosuximide; NCGC00093923-03; 3-Methyl-3-ethylpyrrolidine-2,5-dione; 3-Ethyl-3-methylpyrroline-2,5-dione; Capitus; Ethylmethylsuccimide; Suksilep; LS-147585; Prestwick1_000165; KBio1_000218; CHEMBL696; Prestwick3_000165; Ethymal; C.I. 366; Succimal; Pentinimid; KBio2_001865; .alpha.-Ethyl-.alpha.-methylsuccinimide; ST51037248; Suxinutin; Warner Lambert Brand of Ethosuximide; Etosuximida Faes; Asamid; Ethosuccinimide; Etomal; Aethosuximide [German]; Petnidan; HMS2092D20; Etosuximida; Cl 366; HMS1921L14; D005013; .gamma.-Methyl-.gamma.-ethylsuccinimide; Epileo Petit MAL; Piknole.psi.n; Spectrum2_001483; Lopac0_000532; BSPBio_000029; NINDS_000218; gamma-ethyl-gamma-methyl-succinimide; ethosuximide; UNII-5SEH9X1D1D; H-490; NCGC00093923-02; Pemalin; Succimitin; CI 366; Fortbenton Brand of Ethosuximide; Etosuximide; WLN: T5VMVTJ D2 D1; Atysmal; Succinimide, 2-ethyl-2-methyl-; H 940; Etosuximid; NCGC00093923-01; PM-671; AC1Q2SOO; SPECTRUM1502196; LAB Brand of Ethosuximide; Jenapharm Brand of Ethosuximide; Etosuccimide [DCIT]; 3-Ethyl-3-methylpyrrolidine-2,5-dione; 3-Ethyl-3-methyl-2,5-pyrrolidinedione; .Alpha.-Ethyl-.alpha.-methylsuccinimide; .Gamma.-Methyl-.gamma.-ethylsuccinimide; 2, 5-Pyrrolidinedione, 3-ethyl-3-methyl-; 3-Ethyl-3-methyl-2, 5-pyrrolidinedion; Zaraondan; NCIOpen2_000014; Simatin(E); 2-Ethyl-2-methylsuccinimide; Zarodan; (+-)-2-Ethyl-2-methylsuccinimide; Etosuximida [INN-Spanish]; NCGC00015418-06; PM 671; C07505; e; 3-Ethyl-3-methylpyrroline-2,5-dione; Succinimide, 2-ethyl-2-methyl-; CHEBI:131811; CN-10395; SPBio_001950; Ethosuximidum; Katwijk Brand of Ethosuximide; NSC64013; 77-67-8; 3-Methyl-3-ethylsuccinimide; Pyknolepsinum; Prestwick0_000165; Peptinimid; HMS1568B11; Zartalin; N-Ethyl methylsuccinimide; Prestwick2_000165; BRD-A99633051-001-04-7; Mesentol; DivK1c_000218; 5-21-09-00595 (Beilstein Handbook Reference); Spectrum5_001073; Prestwick_611; DB00593; United Drug Brand of Ethosuximide; AB00052288; 3-Ethyl-3-methylsuccinimide; Spectrum4_001051; Warner-Lambert Brand of Ethosuximide; alpha-Ethyl-alpha-methylsuccinimide; HMS500K20; BRN 0117054
Trade NameZarontin
CompanyPfizer
IndicationEpilepsy
[ICD9: 345   ICD10: G40]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)
InChIKeyHAPOVYFOVVWLRS-UHFFFAOYSA-N
Canonical SMILESCCC1(CC(=O)NC1=O)C    
Therapeutic ClassAnalgesics
CAS NumberCAS 77-67-8
FormulaC7H11NO2
PubChem Compound IDCID 3291.
PubChem Substance IDSID 9708.
SuperDrug ATC IDN03AD01
SuperDrug CAS ID000077678;
TargetVoltage-dependent T-type calcium channel alpha-1G subunitBlocker[2][3][4]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040253 To Reference
Ref 2Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. To Reference
Ref 3Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. To Reference
Ref 4Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001 Mar;415(2-3):141-9. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543